Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A stock ¥197, price ¥184, upside +7.1%, quality 73 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range ¥132.93 – ¥445.32 · fair‑value band ¥141.91 – ¥242.94 · the ¥184.09 price screens below the ¥197.22 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A in your weekly email
Every Wednesday you see whether Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. provides medical devices and solutions in China and internationally.
Show moreShow less
The company offers various products, including patient monitoring, ultrasound, radiology, AED, defibrillation system, anesthesia, CLIA, chemistry, hematology, ventilators, electrocardiograph, endoscope camera system, operating tables, surgical lights, medical supply units, accessories, infusion system, orthopedics, IT Products, cardiovascular intervention, animal medical, and OEM products.
It also provides various solutions, such as M-connect IT, M-connect ER, M-connect ICU, M-connect OR, and M-connect CCU solutions; advanced patient monitoring and intelligent ventilation, emergency ultrasound solutions, and fast defibrillation; customized pendant and critical care ultrasound solutions; precise anesthesia, minimally invasive surgery, infusion system, surgical lights, and anesthesia ultrasound solutions; laboratory diagnostics, medical imaging, and cybersecurity solutions.
The company was founded in 1991 and is headquartered in Shenzhen, the People's Republic of China.
Stock analysis
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760) currently trades at ¥184.09, while our model-based Fair Value estimate is ¥197.22, so the stock looks roughly fairly valued today (gap 6.7%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥180.64 per share, and 5 of the 26 models we run sit above the ¥184.09 price.
Bear case: the Economic Profit group reads lowest at ¥52.47, and 21 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥141.91 (bear) to ¥242.94 (bull), the price of ¥184.09 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A reported revenue of 33.3B CNY in FY2025 versus 25.3B CNY in FY2021, a compound +7.1%/yr. Reported net income was 8.1B CNY in FY2025, compounding +0.4%/yr from FY2021.
Key figures
Market cap 223B CNY (≈ $33.5B) Large · P/E ratio 28.8 · P/S ratio 6.46 · EPS (TTM) ¥6.40 · Dividend yield 2.3% · Net margin 22.4% · Return on equity 18.2% · Return on assets (EBIT) 22.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 84 out of 100 (low confidence).
What moves the price
The share trades about 10% below its 52-week high and 38% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −17% fair-value upside, at 7%, 300760 screens cheaper than that median.
Fair Value models
Bear¥141.91Fair Value ¥197.22Bull¥242.94
Price ¥184.09 · Upside +7.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥1.88 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.84/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−9.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
Start year 2020 (pandemic). Over 10 years: +15.3% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+6.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.1%
Dividend (yield on the price)2.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.4.1% vs 16.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.36% → 30%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +9.3% a year for the price and +6.6% for the forecasts.
AI conclusion: Strong margins and cash flow highlight profitability strength, while insufficient public data leaves most qualitative moat signals thinly evidenced.
Main risk: Centralized volume-based procurement and industry-wide price competition in China could squeeze margins on Mindray's core patient monitoring, diagnostics and imaging products sold to domestic hospitals.
Bull case: Mindray could leverage its expanding overseas revenue share, ecosystem integrations and Qiyuan AI models to offset domestic pricing pressure by winning share in Europe and emerging markets.
Bear case: Persistent domestic price erosion combined with slower overseas adoption might compress overall margins and limit investment in new high-end offerings over the coming years.
Mindray is shifting more toward international markets and newer areas like diagnostics where growth holds up better than at home. Currency fluctuations and softer domestic demand have weighed on profits even as overseas sales accelerate. Will the push abroad and into emerging products outweigh the margin pressures from home and exchange rates, or will those headwinds prove more persistent?
Compare Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 322 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score73 · Top 25%
Fair Value upside+7.1% · Above median
Profitability
Return on equity (12 months)18.2% · Top 25%
Return on assets13.7% · Top 25%
Net margin (12 months)22.4% · Top 25%
Operating margin (12 months)35.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)2.9% · Below median
Dividend yield (12 months)2.3% · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)28.8× · Pricier than median
P/B5.86× · Priciest 25%
P/S (12 months)6.46× · Priciest 25%
Price / free cash flow (fiscal year)27.5× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A Fair Value". https://www.fairvalue-calculator.com/stock/300760
Frequently asked questions
Is Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of ¥197.22 versus a price of ¥184.09, about +7% upside (fairly valued).
What is the fair value of 300760?
Our model-based fair value for Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A is ¥197.22 (as of Nov 3, 2026), built from audited fundamentals. The current price: ¥184.09.
What is the quality score of 300760?
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
Our model-based price target is the fair value of ¥197.22 (as of Nov 3, 2026) from 26 valuation models. Cautious scenario ¥141.91, optimistic scenario ¥242.94. It is a calculation from audited fundamentals, not an analyst target.
What is the Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A stock forecast for 2026?
Our models put fair value at ¥197.22, about +7% upside versus a price of ¥184.09 (fairly valued). Cautious scenario ¥141.91, optimistic scenario ¥242.94. The calculation is refreshed regularly with new filings.
What is the revenue of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A reported trailing-twelve-month revenue of about 34.5B CNY (latest available figure, as of Nov 3, 2026).
Does Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A pay a dividend?
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A currently shows a dividend yield of 2.28% relative to its recent price (as of Nov 3, 2026).
What growth is priced into Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
For today's price to be fair in a discounted-cash-flow model, Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A would have to grow free cash flow by +11.1 % per year for five years (discount rate 8.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.6 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 300760 use?
Our models discount Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A at 8.7 %: a base by market capitalisation (large), damped by beta 0.24, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A that is +11.1 % per year a year over ten years, using the same discount rate (8.7 %) and the same formula as our fair value.
How much growth has Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760) delivered so far?
Over the past 5 years revenue at Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A grew +9.6 % a year. The price currently implies +11.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (+11.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
The free-cash-flow yield on the price is 3.63 %: that much free cash flow Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A produces per unit of market value. When it exceeds the discount rate of our models (8.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A it is ¥197.22 per share (as of Nov 3, 2026), against a price of ¥184.09. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 300760 trades below its calculated fair value: price ¥184.09, fair value ¥197.22, a gap of about +7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300760?
No. The price is what the market pays today (¥184.09); the fair value is what the company's own numbers justify (¥197.22). For Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A the two are ¥13.13 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A worth?
The market values Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A at about 223B CNY (market capitalisation, as of Nov 3, 2026). Per share that is ¥184.09; our models calculate a fair value of ¥197.22 per share.
What do the bullish and bearish scenarios say about 300760?
Our models span a range for Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A: cautious scenario ¥141.91, base ¥197.22, optimistic ¥242.94 per share (as of Nov 3, 2026, price ¥184.09). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300760?
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A trades at a price-to-earnings ratio of 28.8 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥197.22 is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2018 to 2025), reported earnings, FY2025 ex one-offs: 36.3. Other multiples: PEG 2.9, P/B 5.9, P/S 6.5, EV/EBITDA 17.9.
What is the PEG ratio of 300760?
The PEG ratio of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A is 2.90 (P/E divided by earnings growth, as of Nov 3, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
Balance-sheet figures for Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (as of Nov 3, 2026): return on equity 18.2%. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is 300760 from its 52-week high?
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A trades at ¥184.09, about 10% below its 52-week high of ¥204.49 and 38% above the low of ¥132.93 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of ¥197.22 is for.
Which stocks are comparable to Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A stock attractive at the current price?
The data as of Nov 3, 2026: price ¥184.09, calculated fair value ¥197.22 (+7%), Quality Score 73/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300760 calculated?
We run Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥197.22, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A currently trades 7% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
The closing price on Nov 5, 2026 was ¥184.09. Our model-based fair value is ¥197.22, about +7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760) come from?
Earnings per share at Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A grew +26.5 % a year from 2014 to 2024. Broken into its drivers: revenue per share +15.0 %, EBIT margin +12.2 %, tax rate −0.3 %, residual (interest, one-offs) −1.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A
How large is the market capitalisation of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
The market capitalisation of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A is 223B CNY (≈ $33.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
The price-to-sales ratio of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A is 6.46 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
Earnings per share at Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A are ¥6.40 (price ÷ EPS = P/E 28.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
The dividend yield of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A is 2.3% (payout 65.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
The net margin of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A is 22.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
The return on equity (ROE) of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A is 18.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
On an EBIT basis the return on assets of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A is 22.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
The operating margin of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A is 35.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
Revenue at Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A is growing +2.9% versus a year earlier (3y avg +3.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
Earnings per share at Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A are growing −4.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760) hold?
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A holds more cash than debt, 16.5B CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A in the live analysis
One click puts Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 3, 2026